Thalidomide and thrombosis in multiple myeloma

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 3, 2003, Pages 421-422

  Barbui, T ^a   Falanga, A ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

CHEMICALLY INDUCED DISORDER; HUMAN; MULTIPLE MYELOMA; NOTE; RISK; THROMBOSIS; TREATMENT OUTCOME;

HUMANS; MULTIPLE MYELOMA; RISK; THALIDOMIDE; THROMBOSIS; TREATMENT OUTCOME;

EID: 0642341996     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00084.x     Document Type: Note

References (10)

1. Singhal S, Mheta J, Desikan R, Ayers MS, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhopapkar M, Zeldis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 1999; 341: 1565-71.
2. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide. Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-4.
3. Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G. Thalidomide in the management of multiple myeloma. Sem Hematol 2001; 38: 250-9.
4. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. New Engl J Med 2001; 344: 1951-2.
5. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Viju Gopal A, Morris C, Toor A, Siegel E, Fink L, Tricot G. Increased risk of deep vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-5.
6. Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J. Thromboembolic events during treatment with thalidomide. Blood 2002; 99: 4247-8.
7. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G. Activated protein C in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13: 187-92.
8. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Sem Thromb Hemost 1999; 25: 173-82.
9. Falanga A, Barbui T. Coagulopathy of acute promyelocytic leukemia. Acta Haematol 2001; 106: 43-51.
10. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2002; 106: 6-12.